BRPI0915064A2 - derivados de qunoxalinadiona - Google Patents

derivados de qunoxalinadiona

Info

Publication number
BRPI0915064A2
BRPI0915064A2 BRPI0915064A BRPI0915064A BRPI0915064A2 BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2 BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A BRPI0915064 A BR PI0915064A BR PI0915064 A2 BRPI0915064 A2 BR PI0915064A2
Authority
BR
Brazil
Prior art keywords
qunoxalinadione
derivatives
qunoxalinadione derivatives
Prior art date
Application number
BRPI0915064A
Other languages
English (en)
Inventor
Daniel Cravo
Franck Leprife
Sophie Hallakou-Bozec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0915064A2 publication Critical patent/BRPI0915064A2/pt
Publication of BRPI0915064B1 publication Critical patent/BRPI0915064B1/pt
Publication of BRPI0915064B8 publication Critical patent/BRPI0915064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
BRPI0915064A 2008-06-16 2009-05-19 derivados de quinoxalinadiona, seus usos, e medicamentos BRPI0915064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290564 2008-06-16
EP08290564.7 2008-06-16
PCT/EP2009/003538 WO2009152909A1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives

Publications (3)

Publication Number Publication Date
BRPI0915064A2 true BRPI0915064A2 (pt) 2015-10-27
BRPI0915064B1 BRPI0915064B1 (pt) 2019-10-08
BRPI0915064B8 BRPI0915064B8 (pt) 2021-05-25

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915064A BRPI0915064B8 (pt) 2008-06-16 2009-05-19 derivados de quinoxalinadiona, seus usos, e medicamentos

Country Status (25)

Country Link
US (2) US8329698B2 (pt)
EP (1) EP2285786B1 (pt)
JP (1) JP5596676B2 (pt)
KR (1) KR101641391B1 (pt)
CN (1) CN102066342B (pt)
AR (1) AR072148A1 (pt)
AU (1) AU2009259754B2 (pt)
BR (1) BRPI0915064B8 (pt)
CA (1) CA2728018C (pt)
CO (1) CO6321252A2 (pt)
CY (1) CY1114737T1 (pt)
DK (1) DK2285786T3 (pt)
EA (1) EA020236B1 (pt)
EC (1) ECSP11010760A (pt)
ES (1) ES2436195T3 (pt)
HK (1) HK1157784A1 (pt)
HR (1) HRP20131069T1 (pt)
IL (1) IL209421A (pt)
MX (1) MX2010013577A (pt)
MY (1) MY155695A (pt)
NZ (1) NZ590503A (pt)
PL (1) PL2285786T3 (pt)
PT (1) PT2285786E (pt)
SI (1) SI2285786T1 (pt)
WO (1) WO2009152909A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
HUE041544T2 (hu) 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
DK3057953T3 (en) 2013-10-17 2018-11-19 Vertex Pharma CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
WO2020190939A1 (en) * 2019-03-18 2020-09-24 University Of Washington Methods of promoting cellular maturation with ampk activators
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
TWI793877B (zh) * 2020-11-26 2023-02-21 南韓商Ｌｇ化學股份有限公司 作為甘油二酯激酶抑制劑的雜環化合物及其用途
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
NZ336971A (en) 1997-02-18 2000-10-27 American Home Prod 5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists
JP2004538267A (ja) * 2001-05-25 2004-12-24 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのドーパミンｄ２−受容体アゴニスト及びチオトロピウム又はその誘導体の組み合わせ
CN1901917A (zh) * 2004-01-06 2007-01-24 詹森药业有限公司 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3－氧代－3，4－二氢－喹喔啉－2－基－氨基)－苯甲酰胺衍生物和相关化合物
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP2285786B1 (en) 2013-10-09
DK2285786T3 (da) 2013-11-04
CA2728018A1 (en) 2009-12-23
HRP20131069T1 (hr) 2013-12-20
CY1114737T1 (el) 2016-12-14
MY155695A (en) 2015-11-13
US8674097B2 (en) 2014-03-18
US20120322806A1 (en) 2012-12-20
PT2285786E (pt) 2014-01-07
EP2285786A1 (en) 2011-02-23
ES2436195T3 (es) 2013-12-27
CN102066342B (zh) 2013-09-04
BRPI0915064B8 (pt) 2021-05-25
NZ590503A (en) 2012-08-31
SI2285786T1 (sl) 2014-02-28
JP5596676B2 (ja) 2014-09-24
MX2010013577A (es) 2010-12-21
WO2009152909A1 (en) 2009-12-23
AR072148A1 (es) 2010-08-11
EA201100007A1 (ru) 2011-08-30
PL2285786T3 (pl) 2014-01-31
IL209421A0 (en) 2011-01-31
BRPI0915064B1 (pt) 2019-10-08
CA2728018C (en) 2016-10-11
CN102066342A (zh) 2011-05-18
EA020236B1 (ru) 2014-09-30
AU2009259754A1 (en) 2009-12-23
IL209421A (en) 2015-06-30
KR20110017455A (ko) 2011-02-21
ECSP11010760A (es) 2011-02-28
JP2011524384A (ja) 2011-09-01
CO6321252A2 (es) 2011-09-20
US8329698B2 (en) 2012-12-11
AU2009259754B2 (en) 2014-10-02
US20110130404A1 (en) 2011-06-02
KR101641391B1 (ko) 2016-07-20
HK1157784A1 (en) 2012-07-06

Similar Documents

Publication Publication Date Title
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0921327A2 (pt) Combinação de herbicida-protetor
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
FI20080462A0 (fi) Einespakkaus
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI1014454A2 (pt) derivados de isoxazol-pirazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF